日本語 
Kura Oncology, Inc., and Kyowa Kirin Co., Ltd. announced Kura submitted a New Drug Application (NDA) for ziftomenib, a highly selective, once-daily, oral, investigational menin inhibitor, for the treatment of…
Latest News
ModAstera Unveils MAEA, Revolutionizing Medical AI
ModAstera Inc. officially announced its proprietary agent, "Medical AI Engineering Agent (MAEA),"…
Generative AI Boosts Clinical Trial Candidate Selection
The Tokai National Higher Education and Research System, which runs Nagoya University…
Alloy Therapeutics Launches in Japan at Shonan iPark
Alloy Therapeutics Inc., a biotechnology ecosystem company dedicated to democratizing access to…
RevolKa Raises $1.4M in Series A Extension for Therapies
RevolKa Ltd., a venture-backed biotech company providing a cutting-edge AI-driven protein engineering…
Rani Therapeutics signs research deal with Chugai pharma
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. They focus on…
Fujifilm Finds Cancer Targeting Potential in New Peptides
FUJIFILM Corporation announces the successful validation of the cancer cell-targeting potential of…
Rology and the University of Hyogo Sign Landmark R&D MoU to Advance Radiological Innovation
Rology, the leading FDA-cleared teleradiology platform in the MEA region, has signed…
Asahi Kasei and PeptiSystems Team Up on Peptide Tech
Asahi Kasei Bioprocess America (AKBA) and PeptiSystems have formed an exclusive global…
Latest Article
English